PassPort Technologies is a clinical stage drug and medical device development company with its proprietary groundbreaking transdermal microporation platform, PassPort® System. The PassPort® System allows for painless and needle-free delivery of peptides/proteins, antigen/mRNA vaccines, and small molecules via skin. The leading project in our pipelines is Zolmitriptan PassPort®, Best-in-Class, for the treatment of acute migraine with interim positive results in Phase 1 clinical studies. The 2nd clinical candidate, ALC PassPort®, First-in-Class novel peptide drug, is for the treatment of Alzheimer's Disease. PassPort Technologies was founded in 2019 in San Diego, CA and is owned by Axcelead, Inc.